Ironwood Pharmaceuticals (IRWD) Short term Debt (2016 - 2026)

Ironwood Pharmaceuticals (IRWD) posted Short term Debt of $199.9 million for Q1 2026, little changed sequentially from $199.7 million in Q4 2025.

Ironwood Pharmaceuticals (IRWD) Short term Debt (2016 - 2026) Analysis & Trends

Ironwood Pharmaceuticals has reported Short term Debt for 9 years, with the latest figure at $199.9 million in Q1 2026.

Quarterly Short term Debt changed N/A year-over-year to $199.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $199.9 million (changed N/A YoY) and the FY2025 annual result came in at $199.7 million, changed N/A from the prior year.
Short term Debt was little changed at $199.9 million in Q1 2026 per IRWD's latest filing, from $199.7 million in the prior quarter.
Over five years, Short term Debt peaked at $199.9 million in Q1 2026 and troughed at $120.6 million in Q1 2022.
A 5-year average of $190.7 million and a median of $199.5 million in 2025 frame the typical range for Short term Debt.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.94 Bn	42.97 Bn	-
2	Teva Pharmaceutical Industries	42.95 Bn	39.30 Bn	2.15 Bn
3	Zoetis	31.58 Bn	29.90 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.63 Bn	22.83 Bn	5.10 Bn
5	United Therapeutics	22.16 Bn	19.49 Bn	683.80 Mn
6	Viatris	18.75 Bn	17.86 Bn	1.46 Bn
7	Neurocrine Biosciences	15.53 Bn	15.14 Bn	935.80 Mn
8	Elanco Animal Health	11.76 Bn	11.23 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.11 Bn	9.95 Bn	-
10	Ironwood Pharmaceuticals	669.13 Mn	590.00 Mn	-

Download Data